Apotex Health Corp., the Toronto-based pharmaceutical company backed by SK Capital, completed its initial public offering after pricing shares at over 54.1 million units. The stock commenced trading on June 10, 2026 on the Toronto Stock Exchange under the ticker symbol 'APTX.' The offering raised C$1.3 billion, marking a significant milestone for the company's public market debut.

RBC Capital Markets led the underwriting effort with TD Securities Inc. and Scotiabank serving as co-lead managers, joint global coordinators, and joint lead bookrunners. The deal structure reflects strong institutional support for the pharmaceutical company's growth prospects. Goodmans LLP provided Canadian legal counsel to Apotex while Stikeman Elliott LLP advised the underwriting syndicate on legal matters.

The IPO represents SK Capital's successful exit strategy for its portfolio company, providing liquidity to investors while funding Apotex's expansion plans. For the pharmaceutical sector, this listing adds another major player to Canada's public markets and signals continued investor confidence in drug development companies. The C$1.3 billion valuation provides Apotex with substantial capital to pursue strategic acquisitions and research initiatives.

With its public listing secured, Apotex can now access equity markets for future financing needs while increasing transparency around its operations. The company's growth trajectory will be closely watched by healthcare investors seeking exposure to pharmaceutical innovation through Canadian exchanges.